来自MSN19 天
FDA Revokes EUAs of Four COVID-19 Monoclonal Antibodies
The FDA on Friday revoked the emergency use authorizations (EUAs) of four monoclonal antibodies for COVID-19. The four drugs ...
Pharmaceutical Technology2 天
ADG-106 by Adagene Suzhou for Non-Small Cell Lung Cancer: Likelihood of Approval
ADG-106 is under clinical development by Adagene Suzhou and currently in Phase II for Non-Small Cell Lung Cancer.
FierceBiotech9 天
Ikena, after tough year of layoffs, merges with Inmagene to focus on phase 2 dermatitis ...
After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a ...
Pharmaceutical Technology2 天
Muzastotug by Adagene Suzhou for Metastatic Pancreatic Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Pancreatic Cancer.
Taiwan News9 天
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License ...
RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double ...